|
Ophthalmology |
Glaucoma: Lexicon's LX7101 drug candidate is under development as a potential treatment of glaucoma. LX7101 acts by lowering intraocular pressure in the eye.
About the Disease Glaucoma is a group of eye diseases that gradually impair vision and are usually associated with abnormally high intraocular pressure (IOP), fluid pressure within chambers of the eye. All forms of glaucoma damage the optic nerve, and may lead to blindness. While diagnosis and treatment options have improved, many patients still suffer from partial or total vision loss. Risk factors for glaucoma include age, genetic history, diabetes, and nearsightedness. About the Market According to the Glaucoma Research Foundation, glaucoma is estimated to affect 65 million people worldwide, including more than 4 million Americans. According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness in the world, and is the leading cause of blindness in African-Americans. |
|||
